Testicular Function After Immune‐Checkpoint Inhibitors Treatment
Clinical Endocrinology · 2025-11 · 103 (5) · 721-728
DOI: 10.1111/cen.70001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 14.07.2025. Verfasst von Andrea Boutros und 8 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Testis, Melanoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: D.J.H., G.V.L. & A.M.M. were funded by individual NHMRC Investigator Grants..
Abstract (Originalsprache)
Objective
To investigate the effects of immune‐checkpoint inhibitors (ICIs) on spermatogenesis and testicular endocrine function in reproductive‐age men with melanoma.
Design
Prospective, mixed longitudinal and cross‐sectional cohort study. Patients Twenty‐nine men aged 19–46 years undergoing ICI therapy for melanoma at two Australian centres between 2019 and 2024. Three patients were excluded due to subsequent gonadotoxic therapies. The remaining 26 were evaluable.
Measurements
Semen analysis and serum hormone levels (FSH, LH, testosterone) were assessed at baseline and after ICI exposure. Patients with prior cytotoxic chemotherapy or pelvic radiotherapy were excluded.
Results
Among 26 evaluable patients, one man developed persistent azoospermia with marked serum FSH elevation. Overall, median total sperm output per ejaculate declined by 34% (193–127 million per ejaculate) and sperm concentration by 30% (61–43 million/mL), neither statistically significant before or after excluding the case of presumed autoimmune orchitis. On treatment, serum LH and testosterone remained stable while the increase in serum FSH ( p = 0.04) was no longer significant after excluding the single man with auto‐immune orchitis.
Conclusions
ICI treatment may be associated with minimal spermatogenic dysfunction, as reflected by modest reductions in sperm output and increased serum FSH levels, despite preserved serum LH and testosterone concentrations, but mostly due to a rare (4% prevalence) case of autoimmune orchitis. The unpredictability of these effects supports routine fertility preservation counselling in young men before ICI initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
- U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy.
- Andrology Department, Concord Hospital, Concord, New South Wales, Australia.
- Clinical Andrology Laboratory, Concord Hospital, Concord, New South Wales, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, New South Wales, Australia.
ORCID-Profile: Andrea Boutros
Förderung
- D.J.H., G.V.L. & A.M.M. were funded by individual NHMRC Investigator Grants.
Zitieren
APA
Boutros, A., Idan, A., Sleiman, S., Bacha, F., Zhang, T., Jayadev, V., Menzies, A. M., Long, G. V., & Handelsman, D. J. (2025). Testicular Function After Immune‐Checkpoint Inhibitors Treatment. Clinical Endocrinology, 103(5), 721-728. https://doi.org/10.1111/cen.70001
Vancouver
Boutros A, Idan A, Sleiman S, Bacha F, Zhang T, Jayadev V, et al. Testicular Function After Immune‐Checkpoint Inhibitors Treatment. Clinical Endocrinology. 2025;103(5):721-728. doi:10.1111/cen.70001
BibTeX
@article{Boutros2025,
author = {Boutros, Andrea and Idan, Amanda and Sleiman, Sue and Bacha, Feyrous and Zhang, Ting and Jayadev, Veena and Menzies, Alexander M and Long, Georgina V and Handelsman, David J},
title = {Testicular Function After Immune‐Checkpoint Inhibitors Treatment},
journal = {Clinical Endocrinology},
year = {2025},
volume = {103},
number = {5},
pages = {721--728},
doi = {10.1111/cen.70001}
}
EUVIMED